OBJECTS: With improved treatment, many childhood brain tumor survivors live through adulthood. A psychometrically sound instrument, which can capture their unique experiences through the lifetime, is needed. This paper documents the development of the Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor (PedsFACT-BrS) for use with survivors for at least 1 year posttreatment. METHODS: The PedsFACT-BrS was developed in two phases. In phase I, items were generated via interviewing 20 survivors, 20 caregivers, and 12 clinicians/teachers. In phase II, Rasch analysis and classical test theory were used to evaluate the responses of 46 survivors and 46 caregivers. CONCLUSION: The 34-item PedsFACT-BrS covers four domains: physical well-being, emotional well-being and illness experiences, social well-being, and brain tumor-specific concerns. Its scalability is supported by Rasch analysis and its content validity and reliability is documented. It is now ready to be validated to other subpopulations across the disease trajectory.
OBJECTS: With improved treatment, many childhood brain tumor survivors live through adulthood. A psychometrically sound instrument, which can capture their unique experiences through the lifetime, is needed. This paper documents the development of the Pediatric Functional Assessment of Cancer Therapy-Childhood Brain Tumor Survivor (PedsFACT-BrS) for use with survivors for at least 1 year posttreatment. METHODS: The PedsFACT-BrS was developed in two phases. In phase I, items were generated via interviewing 20 survivors, 20 caregivers, and 12 clinicians/teachers. In phase II, Rasch analysis and classical test theory were used to evaluate the responses of 46 survivors and 46 caregivers. CONCLUSION: The 34-item PedsFACT-BrS covers four domains: physical well-being, emotional well-being and illness experiences, social well-being, and brain tumor-specific concerns. Its scalability is supported by Rasch analysis and its content validity and reliability is documented. It is now ready to be validated to other subpopulations across the disease trajectory.
Authors: W L Hobbie; M Stuber; K Meeske; K Wissler; M T Rourke; K Ruccione; A Hinkle; A E Kazak Journal: J Clin Oncol Date: 2000-12-15 Impact factor: 44.544
Authors: Samantha J Anthony; Enid Selkirk; Lillian Sung; Robert J Klaassen; David Dix; Katrin Scheinemann; Anne F Klassen Journal: Qual Life Res Date: 2013-08-02 Impact factor: 4.147
Authors: Jin-Shei Lai; Cindy Nowinski; David Victorson; Rita Bode; Tracy Podrabsky; Natalie McKinney; Don Straube; Gregory L Holmes; Craig M McDonald; Erik Henricson; R Ted Abresch; Claudia S Moy; David Cella Journal: Neurorehabil Neural Repair Date: 2011-07-25 Impact factor: 3.919